

# croma revitalis®

Hyaluronic acid skin booster

Experience long-lasting  
skin rejuvenation.<sup>a,1-4</sup>



Product information for  
healthcare professionals

# Results you can trust:



Improves skin tone after the first injection<sup>2</sup>



Maintains skin hydration<sup>2</sup>



Improves skin elasticity<sup>2</sup>



Provides high and long-lasting patient satisfaction<sup>2</sup>

91.1%


of patients were satisfied with the result at week 12<sup>2</sup>



More than 7 out of 10 patients were satisfied with the result 7 months after the last injection.<sup>d,1</sup>

Croma revitalis® has been shown to significantly increase metabolic activity of human fibroblast cell lines compared to a leading competitor.<sup>4</sup>

In vitro testing showed croma revitalis® provided a positive environment for human fibroblasts, resulting in increased cell numbers compared to non-treated controls.<sup>4</sup>



NM - Normal Medium; FCS – Fetal Calf Serum; WFI – Water For Injections. NM-/FCS WFI: negative control; NM+/FCS WFI: HA raw material  
In vitro metabolic activity of revitalis-treated human fibroblast cell lines relative to controls. p-value \*\* < 0.01

# Non-crosslinked HA improves skin elasticity and skin hydration<sup>2</sup>

The delicate and thin skin of the lateral orbital and perioral areas often require improvement to address issues such as dryness and loss of elasticity.<sup>2</sup>

To replenish the loss of hyaluronic acid (HA) and maintain hydration while improving tone and elasticity, a superficial injection technique such as multipuncture or mesotherapy with a soft product is recommended.<sup>2</sup>

Discover the combined power of:

## Non-Crosslinked hyaluronic acid (HA)

HA helps **retain water** in the skin and **removes free radicals**.<sup>3</sup>

Croma's state of the art manufacturing process ensures that its **pharmacological-grade HA** is of **high molecular weight**- not only in the raw material but also in the final product.<sup>b,4</sup>

High molecular weight HA possesses **anti-inflammatory** properties and is furthermore involved in **wound healing** processes.<sup>5</sup>

## Glycerol

Keeps skin **hydrated + supple** and helps repair its protective **barrier for brighter + smoother skin**.<sup>6</sup>

Also **protects the HA molecules from degradation and strengthens the HA matrix** through hydrogen binding.<sup>3</sup>

The result: enhanced potency of the HA.<sup>3</sup>




**Concentration:** non-crosslinked hyaluronic acid 18mg/1 mL (1.80%). Glycerol 21 mg/1 mL (2.12%)  
| **Pack:** 1 x 1 mL pre-filled syringe co-packed with 2 needles | **Needle:** 30G 1/2" thin wall Terumo™ needle (CE 0197) | **Depth of injection:** Superficial dermal tissue | **Injection technique:** multipuncture technique

# Transformation Gallery

Patients treated with 1mL croma revitalis® with 3 sessions over 8 weeks. The viscoelastic implant was injected intradermally using the multipuncture technique. Key parameters, such as wrinkles, pigmentation, pores and overall texture were measured with VISIA®-CR.



before



14 days after 3<sup>rd</sup> session



before



14 days after 2<sup>nd</sup> session

# Clinically proven effectiveness & safety

**A prospective open label, multicentre study evaluated skin hydration elasticity, firmness and patient satisfaction.<sup>2</sup>**

## Methods:

3 treatments (at baseline, after 3 weeks and again after 6 weeks) with superficial intradermal injections into the lateral canthal (LCL) and perioral lines (PL)

## Month 2

**93%** of the subjects were "satisfied" or "very satisfied"<sup>e,2</sup>

**Firmness** reached statistical significance<sup>2</sup>

## Month 3

**91%** of the subjects were "satisfied" or "very satisfied"<sup>e,2</sup>

**96%** and **98%** of the subjects demonstrated aesthetic improvement in LCL and PL<sup>f,2</sup>

**Hydration & elasticity** reached their peaks<sup>2</sup>

## Month 7

**71%** of the subjects were "satisfied" or "very satisfied"<sup>e,1</sup>



**Convincing safety profile – no serious adverse effects detected in clinical trial.<sup>2</sup>**

e. Each subject was asked to grade their satisfaction with the treatment using one of the following categories: 'Very unsatisfied', 'Unsatisfied', 'Neither unsatisfied nor satisfied', 'Satisfied' or 'Very satisfied' after Week 8, 12 and 16;  
f. Improvement according to investigator using the Global Aesthetic Improvement Scale (GAIS);



# Continuous care at home: Our croma skincare portfolio



With our croma skincare portfolio we are offering a selected range of skincare products to continue skin journeys beyond the clinic.

By providing a recommended skincare regimen to your customers, you can ensure to enhance the clinic experience while also providing your customers a convenient and effective way to take care of their skin between in-clinic visits.\*

\*Please note, that skincare products should only be used on fully healed, intact and undamaged skin.

## AUSTRIA – Headquarters

CROMA-PHARMA GmbH  
Industriezeile 6  
2100 Leobendorf, Austria  
Tel.: +43/2262/68468-0  
E-Mail: office@croma.at

Croma-Pharma UK  
Tel: +44 118 206 6513  
E-Mail: info.uk@cromapharma.com  
<https://at.croma.at>

## For more information visit or scan

 [www.cromapharma.com](http://www.cromapharma.com)

 Croma Pharma UK

 cromapharmauk



**a** The aesthetic effect after initial injection of the viscoelastic implant lasts up to 16 weeks for lateral canthal lines and up to 24 weeks for perioral rhytids.<sup>1</sup>

**b** The HA in the raw material has a MW of 3.2 to  $3.5 \times 10^1$ . The HA in revitalis has a molecular weight of 1500kDa<sup>4</sup>

**c** p-value \*\* < 0.01

**d** Data not shown in the publication

**1** Instructions for use

**2** Sulovsky M, Müller D, Prinz V, Moellhoff N, Cajkovsky M, Duschek N, Frank K. A prospective open-label, multicentre study evaluating a non-cross-linked hyaluronic acid based soft-tissue filler in the correction of lateral canthal and perioral lines. *J Cosmet Dermatol.* 2022 Jan;21(1):191-198. doi: 10.1111/jocd.14460. Epub 2021 Sep 24. PMID: 34559948

**3** Succi, I. B., Da Silva, R. T. & Orofino-Costa, R. 2012. Rejuvenation of periorbital area: treatment with an injectable nonanimal non-crosslinked glycerol added hyaluronic acid preparation. *Dermatol Surg.* 38, 192-198.

**4** Data on file

**5** Bohamiltzky L, Huber AK, Stork EM, Wengert S, Woelfl F, Boehm H. A Trickster in Disguise: Hyaluronan's Ambivalent Roles in the Matrix. *Front Oncol.* 2017 Oct 9;7:242. doi: 10.3389/fonc.2017.00242. PMID: 29062810; PMCID: PMC5640889.

**6** Fluhr JW, Darlenski R, Surber C. Glycerol and the skin: holistic approach to its origin and functions. *Br J Dermatol.* 2008 Jul;159(1): 23-34. doi: 10.1111/j.1365-2133.2008.08643. Epub 2008 Jul 1. PMID: 18510666

**7** Arora G, Arora S, Sadoughifar R, Batra N. Biorevitalization of the skin with skin boosters: Concepts, variables, and limitations. *J Cosmet Dermatol.* 2021 Aug;20(8):2458-2462. doi: 10.1111/jocd.13871

The healthcare professional confirms having informed the consumer of a likely risk associated with the use of the device in line with its intended use. For risks and adverse events associated with the use of the device consult the instructions of use. CE 0123